Neuropharmacology in the Era of Digital Psychiatry: Targeting Glutamatergic Imbalance, Neuro-Inflammation, and Digital Endpoints

Rahul Bobade, Vaishanvi Saste, Arti Mapari, Chakradhar Kadam, Mohan Tale, Dr. Nilesh Sawadadkar, Dr. Nandu Kayande ,

doi:10.5281/zenodo.18251573

Review Paper | Open Access
Volume 03 | Issue 01 | Article Id IJSRT/260401054

Neuropharmacology in the Era of Digital Psychiatry: Targeting Glutamatergic Imbalance, Neuro-Inflammation, and Digital Endpoints
Rahul Bobade* Vaishanvi Saste Arti Mapari Chakradhar Kadam Mohan Tale Dr. Nilesh Sawadadkar Dr. Nandu Kayande
Dr. R. N. Lahoti Institute of Pharmaceutical Education and Research Center, Sultanpur, Maharashtra, India

Abstract

Neuropsychiatric and neurodegenerative disorders represent a major global health burden and are characterized by complex, overlapping pathophysiological mechanisms involving neurotransmitter imbalance, neuroinflammation, oxidative stress, and impaired synaptic plasticity. Traditional neuropharmacological approaches have largely focused on monoaminergic systems; however, these strategies often provide incomplete symptom control and fail to address treatment resistance and disease heterogeneity. Emerging evidence highlights the pivotal role of glutamatergic dysregulation and chronic neuroinflammation as core mechanisms underlying disorders such as major depressive disorder, schizophrenia, bipolar disorder, and Alzheimer�s disease. Concurrently, the rapid evolution of digital psychiatry incorporating wearable sensors, smartphone-based monitoring, artificial intelligence, and digital phenotyping has transformed the way neuropsychiatric conditions are assessed and managed.This review examines the convergence of neuropharmacology and digital psychiatry, emphasizing glutamatergic imbalance and neuroinflammatory pathways as key therapeutic targets. It discusses novel pharmacological strategies, including NMDA receptor modulators, metabotropic glutamate receptor agents, and immunomodulatory therapies aimed at microglial regulation. Additionally, the review highlights the growing importance of digital endpoints and biomarkers in neuropharmacological research, which enable continuous, objective, and real-world assessment of treatment response and disease progression. By integrating molecular, immunological, and digital data streams, precision neuropharmacology offers the potential for individualized, adaptive treatment strategies. Overall, this review underscores how the integration of digital health technologies with advanced neuropharmacological approaches can bridge the gap between biological mechanisms and clinical outcomes. Such multimodal integration is poised to redefine diagnosis, monitoring, and therapeutic optimization in modern psychiatry, paving the way toward personalized and data-driven mental healthcare.

Keywords

Neuropharmacology, Digital Psychiatry, Glutamatergic Dysfunction, Digital Biomarkers, Precision Psychiatry, Artificial Intelligence, Neuropsychiatric Disorders

Introduction

Neuropsychiatric and neurodegenerative disorders such as major depressive disorder (MDD), schizophrenia, bipolar disorder, Alzheimer’s disease (AD), and Parkinson’s disease (PD) represent some of the most complex and heterogeneous conditions in modern medicine. They are characterized by overlapping molecular pathologies including neurotransmitter imbalance, neuroinflammation, oxidative stress, and altered synaptic plasticity [1]. The burden of these disorders is growing worldwide, affecting over 970 million individuals globally according to WHO estimates. Contemporary research indicates that psychiatric and neurodegenerative diseases exist on a biological continuum, with shared etiological pathways involving glutamatergic dysregulation, mitochondrial dysfunction, and immune system activation [2]. Recent neuropharmacological findings emphasize the glutamate system’s central role in excitatory neurotransmission and synaptic plasticity. Dysregulation within this system leads to excitotoxicity and neurodegeneration, underpinning the cognitive and affective disturbances seen in both psychiatric and neurodegenerative disorders [3]. For decades, psychiatric treatment paradigms have revolved around the monoaminergic hypothesis targeting serotonin, dopamine, and norepinephrine. While selective serotonin reuptake inhibitors (SSRIs), dopamine receptor antagonists, and mood stabilizers have provided symptomatic relief, their efficacy remains suboptimal for a substantial proportion of patients, with treatment resistance rates reaching 30–50% in depression and psychosis [4]. Monoaminergic therapies fail to address the complex neuroimmune and glutamatergic mechanisms underlying these conditions. For instance, dopaminergic agents in schizophrenia may alleviate positive symptoms but often exacerbate cognitive and negative symptoms due to downstream glutamate-GABA imbalance [5]. Similarly, antidepressants modulating serotonin do not reverse neuroinflammatory or oxidative changes observed in chronic depression [6]. This has led to the emergence of a paradigm shift towards multi-targeted pharmacology that integrates immunomodulatory, metabolic, and excitatory-inhibitory homeostatic approaches. The integration of digital health technologies collectively termed digital psychiatry is revolutionizing how neuropharmacological data is collected, analyzed, and applied in clinical contexts. Digital endpoints such as smartphone-based behavioral tracking, wearable physiological sensors, and artificial intelligence–driven analytics enable continuous monitoring of neuropsychiatric symptoms [7]. These tools facilitate the identification of digital biomarkers, which complement molecular and neuroimaging biomarkers, leading to real-time quantification of drug efficacy and disease progression [8]. The advent of precision neuropharmacology integrates genomics, transcriptomics, neuroimaging, and digital phenotyping to tailor treatments to individual biological and behavioral profiles. For example, digital phenotyping platforms now allow continuous assessment of cognitive, motor, and affective states through passive data streams, linking behavioral signatures to underlying neurochemical imbalances. This confluence of neuropharmacology and digital psychiatry represents a transformative frontier in mental health, fostering biomarker-driven interventions that adapt dynamically to patient trajectories [9]. This review aims to provide a comprehensive examination of the rapidly evolving intersection between neuropharmacology and digital psychiatry, focusing on the convergence of neurochemical, immunological, and digital paradigms that are reshaping modern mental health research and clinical practice. Central to this discussion is the concept of glutamatergic imbalance, which represents a pivotal neurochemical mechanism underlying a wide spectrum of psychiatric and neurodegenerative disorders. Equally significant is the role of neuroinflammation, not only as a pathological driver but also as a promising biomarker and therapeutic target capable of bridging molecular dysfunctions with clinical manifestations. Complementing these biological dimensions, digital endpoints are emerging as objective, quantifiable measures of treatment response and neurobiological function, offering unprecedented opportunities for continuous, real-time assessment of patient outcomes. By synthesizing the latest advancements from translational neuropharmacology, precision psychiatry, and digital biomarker research, this review highlights how multimodal integration linking molecular insights with digital health innovations can transform future approaches to diagnosis, monitoring, and individualized therapy in psychiatric and neurological disorders.